Liver Cancer (HCC): Symptoms, Causes, Treatment & Nursing Care

In everyday hospital language, liver cancer clusters into two very different problems: primary tumours that start in the liver—almost always hepatocellular carcinoma (HCC)—and metastases from elsewhere (colorectal, breast, melanoma, pancreas) that seed hepatic parenchyma. This article focuses on HCC because it drives cirrhosis surveillance pathways, locoregional therapy suites, and much of hepatology–oncology co-management on general wards.

HCC arises after years of necro-inflammatory stress, altered regeneration, and stepwise genomic change. The lesion you see on multiphase imaging is therefore not just a “mass”; it is the culmination of host biology (viral clearance, alcohol abstinence, metabolic control) and anatomical constraints (portal pressure, collateral vessels). That is why identical tumour diameters can produce different management: a small lesion in a Child-Pugh A patient may meet transplant criteria while the same imaging in a decompensated host may shift the conversation entirely toward comfort-focused care.

Cholangiocarcinoma and other primary rarities sit outside the classic HCC algorithms; when a lesion behaves atypically (dominant hilar location, marked CA19-9 signal without classic HCC risk), MDT discussion usually widens to alternate biopsies or advanced imaging rather than forcing LI-RADS assumptions.

The Barcelona Clinic Liver Cancer (BCLC) schema is the lingua franca that links tumour extent, hepatic reserve, and performance status to first-line treatment class. Nurses rarely calculate staging scores from scratch, but you should recognise which band the patient occupies because it predicts workload: transplant work-up intensity, frequency of groin checks after TACE, or infusion-suite monitoring for checkpoint combinations.

↔On a small screen, swipe or scroll sideways to see the full table.

Exact eligibility for transplant, radiation, or systemic agents varies by centre and trial access; always defer to the signature MDT letter and local formulary rather than memorising historical cut-offs.

Early HCC is often silent—picked up only because six-monthly surveillance found a nodule. Symptomatic presentations usually mean larger volume disease, capsular stretch, biliary obstruction, or complications of portal hypertension rather than the carcinoma itself “hurting” in isolation.

Typical features

• Right-sided heaviness, vague upper abdominal pain, early satiety from splenomegaly or ascites.
• Progressive fatigue, cachexia, and measurable weight loss.
• Worsening ascites or peripheral oedema on prior stable diuretic doses.
• New jaundice or pruritus if cholestasis dominates.

Who looks “atypical”?

• Patients on chronic opioid therapy may downplay discomfort until bilirubin climbs.
• Diabetics with neuropathy may not localise abdominal pain sharply.
• Women and older adults sometimes present with decompensation signs before volunteered tumour symptoms—watch updated LFTs after any new oedema or sleep–wake inversion.

Cirrhosis is the dominant substrate, but high-tier chronic hepatitis B can justify surveillance before bridging fibrosis matures. Alcohol, alcoholic hepatitis relapses, diabetes-associated steatotic disease, and genetic haemochromatosis all funnel into the same end-stage: repeated injury, regenerative nodules, and malignant transformation.

Modifiable vs fixed

• Modifiable: alcohol abstinence, metabolic risk control, antiviral suppression of HBV DNA, HCV cure pathways, weight reduction where steatosis drives fibrosis.
• Harder to modify: male sex (epidemiologic tilt), advancing age, family history, inherited metabolic liver diseases.

Clinical assessment

Apraise nutrition, muscle wasting, stigmata of chronic liver disease, ascites, temporal orientation (covert encephalopathy), and bleeding risk before locking in procedural plans. Medication review should surface NSAIDs, anticoagulant holds, and whether diuretics need adjustment around contrast exposure.

Laboratory investigations

• LFTs, INR, bilirubin, albumin, platelet count (portal hypertension surrogate), creatinine for hepatorenal context.
• AFP trend—useful for surveillance but not a stand-alone diagnostic.
• Aetiologic serologies if presentation is first-time cirrhosis.

Imaging & tissue

Multiphase CT or MRI with liver-protocol timing allows radiologists to apply LI-RADS-style conclusions. Biopsy is reserved for discordant imaging, non-cirrhotic livers, or atypical features.

1. Quantify liver failure & perfusion: Child-Pugh / MELD snapshots, lactate if shocked, urine output trending.
2. Stage tumour burden: confirm imaging, note vascular invasion, extrahepatic disease.
3. Match stage to modality: transplant milieu, surgical candidacy, IR slots, systemic regimen fitness.
4. Install safety netting: bleeding precautions, lactulose adherence for encephalopathy, furosemide/spironolactone monitoring where ascites persists.
5. Define follow-up density: fortnightly labs after systemic start, sooner if sepsis or jaundice spikes.

↔On a small screen, swipe or scroll sideways to see the full table.

Delivered therapy should always trace back to the signed MDT plan; nurses ensure the patient can physically survive the pathway—nutrition, infection screens, renal protection, and psychosocial support.

Curative-intent & liver-directed

• Resection in highly selected non-cirrhotic or modest fibrosis patients with anatomy that leaves adequate future liver remnant.
• Transplant when Milan / extended criteria (per centre) align with biology and lack of contraindications.
• Percutaneous ablation for small lesions when location and biliary proximity permit.
• TACE / transarterial therapies for intermediate-stage multifocal disease; radiation options in specialist centres.

Systemic therapy

Multi-kinase inhibitors (e.g. sorafenib, lenvatinib) and combinations such as atezolizumab plus bevacizumab or pembrolizumab-based schedules occupy advanced disease slots where liver function and perfusion permit. UK licensing layers often emphasise Child-Pugh class A and ECOG performance status—mirror those restrictions when booking daycare beds or counselling patients about expected toxicities.

Supportive measures on the ward

• Careful titration of diuretics and enteral access when malnutrition or encephalopathy complicate intake.
• Pain assessment that avoids stacking hepatotoxic adjuvants without reviewing acetaminophen ceilings.
• Planned blood transfusion support when variceal bleeding or procedural haemorrhage occurs.
• Central line care bundles if long IV therapy is anticipated—line infection in cirrhosis escalates quickly.

• Time-stamp chief events: first hematemesis, first hypotensive reading, antibiotic needle time, contrast administration for imaging.
• Trend weight, abdominal girth, and urine sodium creatinine ratio prompts if ascites therapy changes.
• Pre-TACE: ensure fasting orders, hydration plans, allergy history, and anticoagulant bridging instructions are visible to recovery staff.
• Post-systemic therapy: BP and proteinuria surveillance if regimens pair checkpoint agents with anti-angiogenics per local protocol.
• Communication: use teach-back for “return if fever >38.5 °C, new confusion, black stools, or SOB” instructions.

• Variceal bleeding, coagulopathy, and transfusion-associated volume overload.
• Hepatic encephalopathy, hyponatraemia, renal failure (especially post-diuretic or post-contrast).
• Paracentesis-related complications, line infections, and immune-mediated organ injury on checkpoint therapy.
• Tumour rupture (rare) presenting with peritonitis and haemodynamic collapse.

Vaccinate against hepatitis B where indicated, maximise durable HCV cure rates, maintain alcohol abstinence programmes, and treat metabolic risk early so fewer patients progress to cirrhosis. Surveillance persistence matters: every missed ultrasound window is a missed opportunity for stage migration toward transplantable disease.

Five-year outcomes swing widely with stage at detection and transplant access. Early-stage HCC caught on surveillance carries radically different trajectories than advanced disease presenting with decompensation. Transparent conversations coupled with MDT documentation help nurses reinforce realistic timelines without stripping hope.

What deteriorates first?

Renal numbers often slip before the patient complains—compare creatinine day-to-day whenever diuretics, contrast, or GI losses shift. Encephalopathy may present as subtle sleep reversal before asterixis is obvious.

Documentation that helps the next shift

Note bruising, gum bleeding, last variceal banding date, and any “hold” on anticoagulation. Oncology colleagues need that context when deciding systemic therapy breaks.

• Massive or ongoing GI bleeding, syncope, or oxygen saturation <92% on previously normal air.
• Acute confusion, seizure, or uncontrolled pain after locoregional therapy.
• Fever with abdominal rigidity or refractory vomiting.
• Suspected abdominal pain with shoulder-tip radiation and haemodynamic instability—invoke surgical / IR opinion early.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and cloze drops on the topic of variceal escalation, six-monthly HCC surveillance, TACE versus systemic choreography, and immune checkpoint inhibitor monitoring—mirroring the Clinical Judgment Measurement Model emphasis on noticing risk and acting in safe sequence.